Effect of Irbesartan hydrochlorothiazide combined with Metoprolol in the treatment of elderly patients with severe heart failure
HUANG Shu-wei1YAO Wei-xue1▲ SONG Zhi2KE Dao1KE Zi-fen2
1.Emergency Center,Zhanjiang Central People′s Hospital,Guangdong Province,Zhanjiang 524045,China;
2.Department of Cardiology,Zhanjiang Central People′s Hospital,Guangdong Province,Zhanjiang 524045,China
Abstract：[Abstract]Objective To explore the clinical effect and application value of Irbesartan hydrochlorothiazide combined with Metoprolol in the treatment of elderly patients with severe heart failure.Methods From January 2017 to March 2018,96 cases of elderly patients with severe heart failure were selected as the study subjects in the emergency department and cardiology department of Zhanjiang Central People′s Hospital.They were divided into group A(conventional treatment)and Group B (conventional treatment combined with irbesartan hydrochlorothiazide and metoprolol)by the random number table method,with 48 cases in each group.The clinical efficacy and cardiac function recovery for the two groups were compared at 3 months and 6 months.Results The total effective rate of treatment in group B were higher than that in group A at 3 and 6 months,and the differences were statistically significant(P<0.05).The left ventricular ejection fraction (LVEF)of the two groups at 3 and 6 months afthe treatment were higher than that pre-treatment,and the patientsand heart rate (HR),B-type natriuretic peptide (BNP),systolic blood pressure (SBP),diastolic blood pressure (DBP)were lower than those pre-treatment,and the differences were statistically significant(P<0.05).At 3 and 6 months after treatment,the LVEF of group B were higher than that of group A,while the HR,BNP and SBP in group B were significantly lower than that of group A (P<0.05).At 3 months after treatment,the DBP of the group B was lower than that of group A,and the difference was statistically significant(P<0.05).There were no significant diff erence in the cardiac function of the two groups in the pre-treatment(P>0.05).The cardiac function in the two groupsat3 and 6 monthsaftertreatmentwere significantly better than pre-treatment (P<0.05).The cardiac function in group B were significantly better than that in group A at 3 and 6 months after treatment,and the differences were statistically significant (P<0.05).Conclusion Conventional treatment combined with Irbesartan hydrochlorothiazide and Metoprolol is a safe and effective treatment for elderly patients with severe heart failure.It can significantly improve the clinical symptoms and cardiac function of patients in the short-term and long-term applications.The cardiac function recovery of Patients have a better prognosis.which is worthy applying and promoting in clinical practice.
黄舒伟; 姚为学; 宋智;柯道; 柯子奋. 厄贝沙坦氢氯噻嗪联合美托洛尔治疗老年重症心力衰竭的效果[J]. 中国当代医药, 2019, 26(7): 71-76.
HUANG Shu-wei1YAO Wei-xue1▲ SONG Zhi2KE Dao1KE Zi-fen2. Effect of Irbesartan hydrochlorothiazide combined with Metoprolol in the treatment of elderly patients with severe heart failure. 中国当代医药, 2019, 26(7): 71-76.
McLellan J，Heneghan CJ，Perera R，et al.B-type natriuretic peptide-guided treatment for heart failure[J].Cochrane Data base Syst Rev，2016，22（12）：CD008966.
[2]
Callender T，Woodward M，Roth G，et al.Heart failure care in low-and middle-income countries：a systematic review and meta-analysis[J].PLoS Med，2014，11（8）：e1001699.
[3]
Driscollr A，Meagher S，Kennedy R，et al.What is the impact of systems of care for heart failure on patients diagnosed with heart failure：a systematic review[J].BMC Cardiovasc Disord，2016，16（11）：195.
Levy D，Kenchaiah S，Larson MG，et al.Long-term trends in the incidence of and survival with heart failure[J].N Engl J Med，2002，347（18）：1397-1402.
[8]
Gheorghiade M，Vaduganathan M，Fonarow GC，et al.Rehospitalization for heart failure：problems and perspectives[J].J Am Coll Cardiol，2013，61（4）：391-403.
[9]
Ambrosy AP，Fonarow GC，Butler J，et al.The global health and economic burden of hospitalizations for heart failure：lessons learned from hospitalized heart failure registries[J].J Am Coll Cardiol，2014，63（12）：1123-1133.
[12]
Kemp CD，Conte JV.The pathophysiology of heart failure[J].Cardiovasc Pathol，2012，21（5）：365-371.
[23]
Lawes CM，Hoorn SV，Rodgers A.Global burden of bloodpressure-related disease，2001[J].The Lancet，2008，371（9623）：1513-1518.
[10]
Greene SJ，Fonarow GC，Vaduganathan M，et al.The vulnerable phase after hospitalization for heart failure[J].Nat Rev Cardiol，2015，12（4）：220-229.
[11]
Mozaffarian D，Roger VL，Benjamin EJ，et al.Heart disease and stroke statistics--2013 update：a report from the American Heart Association[J].Circulation，2013，127（1）：e6-e245.
[13]
Bosseau C，Galli E，Donal E.Prognostic value of BNP in heart failure with preserved or reduced ejection fraction[J].Heart，2015，101（23）：1881-1888.
[14]
Lee JH，Lim NK，Cho MC，et al.Epidemiology of heart failure in Korea：present and future[J].Korean Circ J，2016，46（5）：658-664.
[15]
Yancy CW，Jessup M，Bozkurt B，et al.2013 ACCF/AHA Guideline for the management of heart failure：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation，2013，128（16）：e240-e327.
[16]
Flint KM，Allen LA，Pham M，et al.B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes[J].J Am Heart Assoc，2014，3（3）：e000806.
[17]
Kang SH，Park JJ，Choi DJ，et al.Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF[J].Heart.，2015，101（23）：1881-1888.
[18]
Krim SR，Vivo RP，Krim NR，et al.Racial/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure：findings from get with the guidelines-heart failure[J].JACC Heart Fail，2013，1（4）：345-352.
[19]
Al Balushi KA，Habib JQ，Al-Zakwani I.Comparative efficacy of irbesartan/hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure：a retrospective observational study in oman[J].Med Princ Pract，2013，22（3）： 265-269.
[20]
Giles TD，Berk BC，Black HR，et al.Expanding the definition and classification of hypertension[J].J Clin Hypertens，2005，7（3）：505-512.
[21]
Zappe D，Papst CC，Ferber P.Randomized study to compare valsartan±HCTZ versus amlodipine±HCTZ strategies to maximize blood pressure control[J].Vasc Health Risk Manag，2009，5（2）：883-892.
[22]
Qi FH，Chang SS，Yan L，et al.Efficacy and Safety of a Fixed Combination of Irbesartan/Hydrochlorothiazide in Chinese Patients with Moderate to Severe Hypertension[J].Drugs R D，2013，13（2）： 109-117.
[24]
Turnbull F.Blood Pressure Lowering Treatment Trialists′Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events：Results of prospectively-designed overviews of randomised trials[J].The Lancet.2003，362（9395）：1527-1535.
[25]
Mancia G，Fagard R，Narkiewicz K，et al.2013 ESH/ESC Guidelines for the management of arterial hypertension：the task force for the management of arterial hypertension of the European Society of Hypertension （ESH）and of the European Society of Cardiology （ESC）[J].Blood Pressure，2014，23（1）：3-16.
[26]
Ettore M，Stefano O，Gianfranco P.Blood pressure response tozofenoprilorirbesartaneachcombined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy：a Randomized，double-Blind，controlled，parallel group，noninferiority trial[J].Int J Hypertens，2015，8（5）：139 465.
[27]
Molenaar P，Christ T，Hussain RI，et al.PDE3，but not PDE4，reduces β1-and β2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients[J].Br J Pharmacol，2013，169（3）：528-538.
[28]
Ajam T，Ajam S，Devaraj S，et al.Effect on mortality of higher versus lower β-blocker（metoprolol succinate or carvedilol）dose inpatients with heart failure[J].Am J Cardiol，2018，122（6）：994-998.
[29]
Peter Bramlage.Fixed combination of irbesartan and hydroch lorothiazide in the management of hypertension[J].Vasc Health Risk Manag，2009，5（1）：213-224.
京公网安备 11010502046607号